Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Patients With Moderate To Severe Periodontitis Need Evaluation For Heart Disease Risk
Additional research is called for and patients with moderate to severe periodontitis should receive evaluation and possible treatment to reduce their risk of atherosclerotic cardiovascular disease (CVD), according to a special consensus paper by editors of The American Journal of Cardiology and Journal of Peridontology in the July 1, 2009 issue of The American Journal of Cardiology, published by Elsevier.
generic viagra online
Swine Influenza Daily Update: 16 July 2009, Wales
The NPHS influenza surveillance scheme, which records reports of diagnoses of flufrom more than 300 GP practices across Wales, shows low but increasing levels of influenza activity across Wales. Further detail can be found on the NPHS website.
News of the day
Pioneering Research Into Healing Power Of Sugar
A pioneering University of Wolverhampton lecturer has won a ÷£25,000 grant to research the healing effect of sugar on cuts and wounds.
Diagnostics

Eurand Successfully Completes Registration Procedure For Paracetamol ODT 250 And 500 Mg In The European Union

Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced that the Dutch Medicines Evaluation Board (MEB) informed the Company that the Decentralized Procedure (DCP) for registration of Paracetamol 250 and 500 mg Orodispersible Tablets (ODT) in several EU countries has been successfully completed. In addition to The Netherlands, which acted as the reference member state, the DCP involved the United Kingdom, Germany, France, Italy and Spain. Formal approval is now expected from each country by the end of 2009. Eurand is actively seeking a partner to market and distribute Paracetamol ODT in these countries. Paracetamol (also known as acetaminophen) is a widely used analgesic (pain reliever) and antipyretic (fever reducer). Paracetamol ODT is indicated for symptomatic treatment of mild-to-moderate pain and/or fever. The 500 mg dose is indicated in adults and adolescents (over 12 years old) only, and the 250 mg dose is for use in children from the age of four and adolescents only. The product may be taken with or without liquid. "We are pleased by the Dutch MEB"s decision regarding our Paracetamol ODT, and we look forward to receiving approval in the six individual countries later this year," said GearĂöid Faherty, Chairman and Chief Executive Officer. "We believe our formulation will deliver this well-recognized pain reliever in a more patient friendly manner, particularly for those patients who have difficulty swallowing." He noted that this is the second ODT formulation that Eurand has had approved this year. In May 2009, the FDA approved EUR-1048, marketed by GlaxoSmithKline as Lamictal® ODT™ (lamotrigine) Orally Disintegrating Tablets. Like Paracetamol ODT, Lamictal ODT uses Eurand"s AdvaTab® orally disintegrating tablet (ODT) and Microcaps® taste-masking technologies. Eurand


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009